publications
Phase 1 and 2 Studies Demonstrate the Safety and Efficacy of Intraprostatic Injection of PRX302
Article published on November 24, 2011
Samuel Denmeade et al.
Background: PRX302 is a prostate specific antigen (PSA)–activated pore-forming protein toxin under development as a targeted approach for improving lowerurinary tract symptoms (LUTS) caused by
SIU 2009 Poster
Poster published in 2009
Samuel Denmeade et al.
PRX302 is a transperineally administered, PSA-activated protoxin that produces symptomatic relief in men with moderate to serve BPH.